Clinical trials: Geriatric Disorders
Attention-Deficit/Hyperactivity Disorder
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
To assess the efficacy of optimized Extended-release Guanfacine Hydrochloride compared with placebo in the treatment of adolescents aged 13-17 years with a diagnosis of ADHD as measured by the ADHD-RS-IV
- Trial name
- NCT01081132
- Testing
- Extended-release Guanfacine Hydrochloride
- Where
- 54 sites in United States
- Volunteers
- 314 people
- Sponsor
- Shire
Urinary Bladder, Overactive
A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment.
- Trial name
- SOFIA (NCT00798434)
- Testing
- Fesoterodine fumarate
- Where
- 60 sites in Austria, Belgium and 13 more
- Volunteers
- 794 people
- Sponsor
- Pfizer
Poliomyelitis
A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine
This will be a single center, age de-escalation, partly-blinded, randomized study. The trial will be performed with the participation of 100 healthy children age 1-5 years who have been vaccinated with inactivated polio vaccine…
- Trial name
- NCT03554798
- Testing
- nOPV2 (monovalent oral polio vaccine)
- Where
- 2 sites in Panama
- Volunteers
- 1,025 people, healthy volunteers welcome
- Sponsor
- Fidec Corporation
Lymphocytic Leukemia, Chronic
A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia
This single arm, open-label study will assess the safety and efficacy of low dose fludarabine and cyclophosphamide in combination with standard dose MabThera/Rituxan (rituximab) as primary therapy in elderly patients (>/= 65…
- Trial name
- NCT01263704
- Testing
- Cyclophosphamide, Fludarabine, Rituximab
- Where
- 12 sites in Israel
- Volunteers
- 42 people
- Sponsor
- Hoffmann-La Roche
Pandemic Influenza Disease
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
The present study, phase III, randomized, controlled, observer-blind, multicenter study, will evaluate safety, tolerability and immunogenicity of two doses of an adjuvanted monovalent influenza vaccine compared with an adjuvanted…
- Trial name
- NCT00841763
- Testing
- Trivalent influenza virus vaccine (TIV), Adjuvanted monovalent influenza virus vaccine (aH5N1), Adjuvanted trivalent influenza virus vaccine (aTIV)
- Where
- 2 sites in Finland, Germany
- Volunteers
- 3,647 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
Safety and Reactogenicity of FluBlok and Comparison of Immunogenicity, Efficacy and Effectiveness Against TIV
The purpose of this study was to evaluate and compare the safety, reactogenicity, immunogenicity, relative efficacy and effectiveness of FluBlok to a licensed trivalent influenza vaccine (TIV)in healthy adults age 50-64 years.
- Trial name
- NCT00539864
- Testing
- FluBlok Influenza Vaccination, TIV (Fluzone) Influenza Vaccination
- Where
- 5 sites in United States
- Volunteers
- 602 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Hematologic Malignancy
Patient-Centered Care for the Older Adult With Hematologic Malignancy
This research study is evaluating if co-management by a geriatrician embedded in the oncology clinic can improve outcomes for frail older adults with blood cancers.
- Trial name
- NCT02359838
- Testing
- Baseline Geriatric Screening/Assessment, Geriatrician Co-Management
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Dana-Farber Cancer Institute
Infections, Papillomavirus
Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Indeed, certain oncogenic types of HPV can infect the cervix (part of the uterus or womb).
- Trial name
- NCT00316693
- Testing
- HPV-16/18 vaccine (Cervarix™), Aimmugen™
- Where
- 4 sites in Japan
- Volunteers
- 1,046 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
This study will evaluate the efficacy of the RSVPreF3 OA investigational vaccine in preventing Lower Respiratory Tract Disease (LRTD) caused by RSV in adults ≥60 years of age following a single dose of the RSVPreF3 OA vaccine and…
- Trial name
- NCT04886596
- Testing
- RSVPreF3 OA vaccine
- Where
- 277 sites in United States, Australia and 15 more
- Volunteers
- 26,675 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Intraepithelial Neoplasia
A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects
The purpose of this prospective, multi-centre, PMS cohort study was to monitor the safety of Cervarix, which is the first HPV vaccine licensed for use in China, to help prevent cervical cancer caused by HPV types 16 and 18.
- Trial name
- NCT03438006
- Testing
- Safety data collection (following routine vaccination)
- Where
- 7 sites in China
- Volunteers
- 3,016 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chagas Disease
A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi
Researchers are looking for a better way to treat children who have an infectious disease caused by the parasite Trypanosoma cruzi (Chagas' disease).
- Trial name
- NCT02625974
- Testing
- Nifurtimox (Lampit, BAYA2502)
- Where
- 25 sites in Argentina, Bolivia and 1 more
- Volunteers
- 330 people
- Sponsor
- Bayer
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00891878
- Testing
- capecitabine, sunitinib malate
- Where
- 182 sites in United States
- Volunteers
- 12 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Allergic Rhinitis, Chronic Urticaria
Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months
To determine the safety of levocetirizine in children ages 6-11 months with symptoms of allergic rhinitis or chronic idiopathic urticaria.
- Trial name
- BALL (NCT00628108)
- Testing
- Levocetirizine 1.25 mg
- Where
- 26 sites in United States
- Volunteers
- 69 people
- Sponsor
- UCB Pharma
Prostate Cancer
Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation
This is a study of HMB plus amino acids in older men with prostate cancer starting androgen deprivation therapy (ADT). The investigators hypothesize that the use of this nutritional supplementation will decrease the loss of…
- Trial name
- NCT01607879
- Testing
- Standard of care ADT + (HMB + arginine + glutamine), Standard of care ADT
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Medical College of Wisconsin
Metabolic Syndrome
P20 Extending Sleep to Reverse Metabolic Syndrome
This pilot study will test the acceptability and feasibility of a sleep extension intervention in community-dwelling, short-sleeping, racially/ethnically diverse middle-aged adults with MetS.
- Trial name
- NCT03596983
- Testing
- Sleep Intervention, Week 2 Intervention
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- NYU Langone Health
Varicella
Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).
This study aims to assess the immunogenicity and safety of varicella vaccination in a population of autologous peripheral stem cell/ bone marrow transplantation recipients who have reached at least four months…
- Trial name
- NCT00792623
- Testing
- VarilrixTM
- Where
- 3 sites in Australia
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Hearing Impairment
CROS and Quality of Life of Elderly Cochlear Implant Recipients and Their Care Givers
The purpose of this study is to assess the effect of the Naida Link contralateral routing of signal (CROS) device on speech understanding in challenging listening situations and on the quality of life in unilateral CI recipients…
- Trial name
- NCT04794179
- Testing
- Naida Link CROS
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Utah
Lung Cancer
First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC
This trial will look at 2 different drug combinations that have well known safety profiles and are known to be active against non small cell lung cancer and combine them with bevacizumab, an experimental drug that has shown…
- Trial name
- NCT00456261
- Testing
- Pemetrexed, Gemcitabine, Bevacizumab
- Where
- 18 sites in United States
- Volunteers
- 110 people
- Sponsor
- SCRI Development Innovations, LLC
Osteoporosis, Postmenopausal, Osteoporosis
Preventing Osteoporosis Using Denosumab
The purpose of this research study is to find out if denosumab (Prolia®), an injection given in the arm under the skin every 6 months, works to treat bone loss and prevent it from worsening in older men and women (ages 65 and…
- Conditions
- Osteoporosis, Postmenopausal, Osteoporosis, Osteoporotic Fractures
- Trial name
- PROUD (NCT02753283)
- Testing
- denosumab, Calcium and Vitamin D
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Susan L. Greenspan
Wilson Disease
Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients
The main purpose of the study was to evaluate the efficacy of ALXN1840 (formerly WTX101) for 24 weeks on non-ceruloplasmin-bound copper (NCC) concentrations adjusted for molybdenum plasma concentration in participants newly…
- Trial name
- NCT02273596
- Testing
- ALXN1840
- Where
- 9 sites in United States, Austria and 3 more
- Volunteers
- 29 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.